There are a number of translational funding opportunities available to UCL and partner researchers internally and externally. The TRO helps PIs identify the most suitable scheme for their project.
These funds differ from standard project grants by being milestone driven with clear go/no go decision criteria which require active project management. Please find an overview of the translational funding landscape for UCL academics below:
Internal (Proof-of-Concept) Funding Opportunities
- UCL Therapeutic Acceleration Support (TAS) Fund - A list of previous TAS fund awarded projects can be found here.
- Biomedical Research Centre (BRC) Fund
- EPSRC Impact Acceleration Award Funding
- Internal Venture Funding (from the UCL Technology Fund and the Apollo Fund)
- UCL Therapeutic Innovation Networks (TINs) pilot data funding schemes (more details on the TINs website)
- TIN Pilot Data Funding Schemes - Now CLOSED
These funding schemes for early career researchers, are made available through the UCL/Wellcome Trust Translational Partnerships Award. For more information, visit the UCL Therapeutic Innovation Networks (TINs) website: https://www.ucl.ac.uk/therapeutic-innovation-networks/funding-opportunities
- Therapeutic Acceleration Support (TAS) Fund - Call 8 - Now CLOSED
- Deadline for Applications: Friday 9th October 2020, 5pm
The UCL Therapeutic Acceleration Support (TAS) Fund is supported by the MRC Confidence in Concept scheme, Wellcome Trust Institutional Strategic Support Fund and the three Biomedical Research Centres (BRC) affiliated with UCL (University College London Hospitals NHS Foundation Trust (UCLH) BRC, Great Ormond Street Hospital (GOSH) BRC and Moorfields BRC.
It aims to accelerate the transition from discovery science to the early stages of therapeutic development by providing responsive and flexible funding to support preliminary translational work.
The scheme expects to typically fund individual projects in the range of £60-75K (directly incurred costs only) for up to 12 months.
Remit of this Call
- All modalities of therapy and diagnostics including engineering/medical technology and bioinformatics approaches can be submitted for consideration. Applications from across the breadth of diseases researched in UCL and its partner hospitals will be welcomed.
- Applications with an industry partner are strongly encouraged.
- Before applying please read the Application Brief to ensure that your project is in remit. Applications that do not conform to the brief will not be considered for funding.
External Funding Opportunities
- MRC Developmental Pathway Funding Scheme (DPFS)
- NIHR Invention for Innovation (i4i) Scheme
- Charity Schemes (Wellcome, LifeArc, BHF)
- Industry Partnerships
Open External Translational Funding Opportunities:
- CENTRES FOR THERAPEUTIC INNOVATION (CTI) - Requesting proposals for novel therapeutic targets with application
across Pfizer’s core therapeutic areas
In 2010, Pfizer launched the Centre for Therapeutic Innovation (CTI),which was founded on the notion that scientific and global health challenges are to be tackled collaboratively. CTI collaborates with academic institutions and investigators to advance great science, and accelerate concepts from the laboratory into viable therapies for the benefit of patients.
Pfizer is still actively seeking opportunities to launch further research collaborations with UCL and other HEI’s across Europe and the USA and has available funding to support exploratory collaborative research programmes of work.
Please find the 2021 Call for Proposal (CFP) here, which outlines their areas of interest.
Interested applicants will be provided with support in terms of initial discussions of the proposal, guiding the application process and liaising with the Tech Transfer Office (UCLB) before submission.
To apply, PIs should submit the Pre-proposal form below to Tina Osadolor (email@example.com) in the Translational Research Office (TRO) by June 28th 2021.
- Astellas Pharmaceutical
Astellas Pharma, an international pharmaceutical company with a long record of academic engagement. Our client is looking for academic research projects and technologies utilising small molecule compounds with significant in vivo efficacy that have the potential to reverse disease pathophysiology. You can find more information about Astellas' current interests here.
Interested applicants will be provided with support in terms of initial discussions of the proposal, guiding the application process and liaising with IN-PART the platform that has advertised this opportunity on behalf of Astellas submission.
The requirement for this opportunity is 200-300 words of publicly available information, or a one page brief summarising the opportunity.
Deadline for PIs to submit proposals to Tina Osadolor firstname.lastname@example.org – July 20th 2020. Please also contact Tina for any further queries relating to this call.
- The Association of the British Pharmaceutical Industry (ABPI)
The ABPI has developed a tool to help build research relationships between the pharmaceutical industry and UK academics. The Library of Initiatives for Novel Collaborations (ABPI LINC) is intended to provide a research database which will provide easy access to identify new collaboration opportunities.
- Industrial Connectivity Awards - NOW CLOSED
UCL TRO invites members of the UCL community to apply for funding under the Proximity-to-Discovery award which was granted to the TRO from the MRC. The Industry Connectivity Awards are suitable for UCL researchers looking to promote their engagement with industry.
- The Neurogenetic Therapies Programme - Now CLOSED
The Neurogenetic Therapies Programme, funded by the Sigrid Rausing Trust, aims to accelerate the development and testing of novel genetics-based therapies for neurodegeneration and dementia. Preclinical and clinical projects will be supported in order to create a pipeline of new translational genetic therapies, from concept through to patients. Projects will be supported by both preclinical and clinical steering committees, as relevant. Therapeutic modalities may include, but not are limited to, viral delivered gene therapies, antisense oligonucleotide approaches. Novel approaches to delivery of neurogenetic therapies will also be considered. Partnerships with industry are welcome, as is co-funding from other sources.
The programme will provide awards between £10,000 to £250,000 to be used flexibly and against specific milestones.
- Request For Proposals open: 23 March 2020
- Proposals due: Midday 18 May 2020
- Recipients announced: July 2020
- Awards start: August 2020
For more information on selection criteria and requirements, please download the Request for Proposals PDF below:
To apply, proposals must be submitted using the Neurogenetic Therapies Programme Expression of interest template attached below and emailed to email@example.com with the subject line Neurogenetics proposal [Name of applicant].
For more information about any translational funding schemes, to apply or to work out which scheme is best for you, please contact the Translational Research Group within the TRO.